KR20120080579A - 암 치료와 예방에 있어 메트포르민의 사용 - Google Patents

암 치료와 예방에 있어 메트포르민의 사용 Download PDF

Info

Publication number
KR20120080579A
KR20120080579A KR1020127007261A KR20127007261A KR20120080579A KR 20120080579 A KR20120080579 A KR 20120080579A KR 1020127007261 A KR1020127007261 A KR 1020127007261A KR 20127007261 A KR20127007261 A KR 20127007261A KR 20120080579 A KR20120080579 A KR 20120080579A
Authority
KR
South Korea
Prior art keywords
metformin
cancer
cells
tumor
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127007261A
Other languages
English (en)
Korean (ko)
Inventor
케빈 슈트룰
헤더 허쉬
디미트리오스 일리오폴로스
Original Assignee
프레지던트 앤드 펠로우즈 오브 하바드 칼리지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 filed Critical 프레지던트 앤드 펠로우즈 오브 하바드 칼리지
Publication of KR20120080579A publication Critical patent/KR20120080579A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127007261A 2009-08-25 2010-08-25 암 치료와 예방에 있어 메트포르민의 사용 Withdrawn KR20120080579A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23677809P 2009-08-25 2009-08-25
US61/236,778 2009-08-25

Publications (1)

Publication Number Publication Date
KR20120080579A true KR20120080579A (ko) 2012-07-17

Family

ID=43733025

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127007261A Withdrawn KR20120080579A (ko) 2009-08-25 2010-08-25 암 치료와 예방에 있어 메트포르민의 사용

Country Status (14)

Country Link
US (1) US20120220664A1 (cg-RX-API-DMAC7.html)
EP (1) EP2470170A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013503171A (cg-RX-API-DMAC7.html)
KR (1) KR20120080579A (cg-RX-API-DMAC7.html)
CN (1) CN102596192A (cg-RX-API-DMAC7.html)
AU (1) AU2010292599A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012004281A2 (cg-RX-API-DMAC7.html)
CA (1) CA2772120A1 (cg-RX-API-DMAC7.html)
IL (1) IL218287A0 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN01964A (cg-RX-API-DMAC7.html)
MX (1) MX2012002337A (cg-RX-API-DMAC7.html)
SG (1) SG178556A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011031474A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201201434B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011084523A2 (en) * 2009-12-15 2011-07-14 The Salk Institute For Biological Studies Ulk1 compositions, inhibitors, screening and methods of use
AU2011339929B2 (en) * 2010-12-06 2017-05-11 Tom C. Tsang Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
WO2012171015A2 (en) * 2011-06-10 2012-12-13 Translational Genomics Research Institute Therapeutic combination for cancer treatment
CN102327256B (zh) * 2011-09-22 2014-01-29 上海交通大学医学院附属瑞金医院 二甲双胍在制备治疗淋巴瘤疾病药物中的应用
WO2013086002A1 (en) * 2011-12-05 2013-06-13 Cellworks Research India Private Limited Compositions, process of preparation of said compositions and method of treating cancer
CA2898113C (en) 2013-01-14 2022-05-31 Health Clinics Limited Combination cancer therapeutics and uses thereof
SG11201509707QA (en) 2013-04-12 2015-12-30 Rebecca Lambert Bent Cancer therapy
JP6242071B2 (ja) * 2013-04-23 2017-12-06 国立大学法人 岡山大学 免疫疲弊cd8+t細胞の機能改善薬、がん治療薬及びメタボリック症候群の予防または治療薬
JP6440212B2 (ja) 2013-05-24 2018-12-19 株式会社加齢・栄養研究所 メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
CN107205968B (zh) * 2014-08-14 2021-08-20 威斯康星州医药大学股份有限公司 修饰的线粒体-二甲双胍化合物及其合成和使用方法
SG10202005315SA (en) * 2014-08-19 2020-07-29 Nat Univ Corporation Okayama Univ Agent for treating and/or preventing diseases associated with immune abnormalities by combining biguanide antidiabetic drug with immunosuppressive factor blocking agent or costimulatory receptor agonist
WO2016026933A1 (en) * 2014-08-21 2016-02-25 Centre National De La Recherche Scientifique - Cnrs - Adjuvant or neoadjuvant therapy for sensitizing cancer stem cells to chemotherapy
CN109072312A (zh) * 2016-02-16 2018-12-21 新加坡科技研究局 癌症表观遗传谱分析
WO2018044369A2 (en) 2016-05-19 2018-03-08 The Regents Of The University Of California Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
CN106727468A (zh) * 2017-04-01 2017-05-31 四川大学 二甲双胍及联合二甲双胍和长春新碱在制备治疗白血病药物中的应用及药物组合物
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン:癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
WO2019183003A1 (en) * 2018-03-18 2019-09-26 The University Of North Carolina At Chapel Hill Methods and assays for endometrial diseases
CN111617255B (zh) * 2019-02-28 2023-08-18 北京强新生物科技有限公司 用于治疗中枢神经系统紊乱的组合疗法
KR102312100B1 (ko) * 2020-06-05 2021-10-14 (주)프론트바이오 항바이러스제 및 항우울제를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
WO2024233616A1 (en) * 2023-05-11 2024-11-14 Wainer Irving W Method for treating cancer
WO2025085311A1 (en) * 2023-10-16 2025-04-24 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of kmt2d-deficient cancers
WO2025157212A1 (zh) * 2024-01-23 2025-07-31 成都夸常奥普医疗科技有限公司 包含n,n-二甲基亚双胍的制剂、和包含n,n-二甲基亚双胍与药物的药物组合、组合物、试剂盒及其用途和制备方法
WO2026119290A1 (zh) * 2024-12-05 2026-06-11 成都夸常奥普医疗科技有限公司 局部药剂的新用途、新治疗方法、相关制剂、和试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005284798B2 (en) * 2004-09-15 2012-02-02 The President And Fellows Of Harvard College Reducing ER stress in the treatment of obesity and diabetes
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
DE102006026026A1 (de) * 2006-06-01 2007-12-06 Grünenthal GmbH Arzneimittel
WO2008097861A2 (en) * 2007-02-02 2008-08-14 Braincells, Inc. MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
WO2008110491A2 (en) * 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
WO2009101199A2 (en) * 2008-02-15 2009-08-20 Bodo Melnik Treatment of acne vulgaris; rosacea and rhinophym

Also Published As

Publication number Publication date
BR112012004281A2 (pt) 2016-03-08
WO2011031474A2 (en) 2011-03-17
CN102596192A (zh) 2012-07-18
AU2010292599A1 (en) 2012-03-15
IL218287A0 (en) 2012-04-30
MX2012002337A (es) 2012-06-25
EP2470170A4 (en) 2013-01-02
SG178556A1 (en) 2012-03-29
US20120220664A1 (en) 2012-08-30
ZA201201434B (en) 2013-05-29
IN2012DN01964A (cg-RX-API-DMAC7.html) 2015-08-21
CA2772120A1 (en) 2011-03-17
EP2470170A2 (en) 2012-07-04
JP2013503171A (ja) 2013-01-31
WO2011031474A3 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
US20120220664A1 (en) Use of metformin in cancer treatment and prevention
ES2863996T3 (es) Terapia de combinación para el tratamiento del cáncer
Jia et al. Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo
Aranda et al. Nitric oxide and cancer: the emerging role of S-nitrosylation
EP3967303A1 (en) Inos-inhibitory compositions and their use as breast cancer therapeutics
CN112218658A (zh) 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
Yu et al. ADT-OH exhibits anti-metastatic activity on triple-negative breast cancer by combinatorial targeting of autophagy and mitochondrial fission
WO2016145298A1 (en) METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS
EP2968379B1 (en) Etoposide prodrugs for use in targeting cancer stem cells
Mayer et al. Perampanel attenuates epileptiform phenotype in C6 glioma
KR20190084291A (ko) 암 치료를 위한 제약 조성물 및 방법
WO2020230701A1 (ja) 抗腫瘍剤及び配合剤
JP2017527615A (ja) 線維化疾患及び癌を治療するための組成物及び方法
US11583509B2 (en) Compound for treating cancer and diabetes
KR20190089191A (ko) 티로신 유도체 및 이들을 포함하는 조성물
US20210106552A1 (en) Methods for treating triple negative breast cancer using salvianolic acid b
JP2021517886A (ja) 口腔癌治療用の医薬の製造ためのジンセノサイドm1の使用
WO2014085485A1 (en) Methods and compositions for targeting cancer stem cells
US10792331B2 (en) Methods for reducing cardiotoxicity from chemotherapy by administering humanin analog compositions
HK1173378A (en) Use of metformin in cancer treatment and prevention
Vasudevan et al. Efficacy of pazopanib on primary patient-derived undifferentiated malignant round cell sarcoma line
Yang et al. Gallium maltolate and cisplatin co-treatment effectively targets triple-negative breast cancer in spheroid and mouse models
O’Connor et al. New drugs for the treatment of advanced-stage diffuse large cell lymphomas
CN110627733A (zh) 一种抗肿瘤小分子化合物的作用机制及应用
Al-Rawashde et al. Epigenetic Reactivation of SOCS-3 and Inhibition of ERK1/2 Underlie Thymoquinone-Induced Apoptosis in a Chronic Myeloid Leukemia Xenograft Model

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120320

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid